BillionToOne
Business Services · California, United States · 501-1,000 Employees
View Company Info for Free
Overview
Headquarters
1035 Obrien Dr, Menlo Park, California, ...Phone Number
(650) 460-2551Website
www.billiontoone.comRevenue
$397.4 MillionStock Symbol
BLLNIndustry
ZI Rank: 2
Signal Type
Mar
Apr
May
Jun
Jul
Aug
ZI Rank
4
1
2
3
4
2
About BillionToOne
BillionToOne, headquartered in Menlo Park, California, is a precision diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's patent-pending QCT molecular counter platform is the only technology platform that can accurately count DNA molecules to the single-count level. BillionToOne's flagship product, UNITY, is the first and only noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis (CF), spinal muscular atrophy (SMA), and hemoglobinopathies through maternal blood.Explore more
BillionToOne Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is BillionToOne your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Product Launch: Get notified when BillionToOne launches new products
BillionToOne, which may be a good buyer, showed buying intent in Masked Content Topic
Check if BillionToOne has recently received funding, and reach out quickly before it becomes old news!
Check out if BillionToOne is spiking on competitors!
Click to see if BillionToOne had a recent Job posting/layoffs
Earning: See what the market has to say on BillionToOne recently announced quarterly report
Congratulate Masked Content for being promoted to Masked Content at BillionToOne
Funding: Get notified immidiatlly once BillionToOne has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined BillionToOne as Masked Content
Find 3 more new buyers
Compare Similar Companies to BillionToOne
Compare insights from companies similar to BillionToOne, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
BillionToOne is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
BillionToOne is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about BillionToOne.
BillionToOne financials insights
Gather financial insights about BillionToOne, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$15M
2021
Series B
$55M
2022
Series C
$125M
Unspecified
$48.5M
2024
Series D
$130M
2025
IPO
$273.1M
BillionToOne Tech Stack
A closer look at the technologies used by BillionToOne
Most Recent Scoops
Facilities Relocation / Expansion
BillionToOne has signed a lease for a dedicated 62,000-square-foot oncology production lab in Union City, California, located directly across from its existing prenatal production lab. Design and build-out are underway, with production expected by the end of 2027, and the facility is designed to support oncology testing capacity of approximately 5,000 tests per day over time.
Facilities Relocation/Expansion, Capacity Planning, Leasing
Product Launch
BillionToOne has announced the expansion of Northstar Select to 102 genes, effective September 1, to cover recent and upcoming FDA therapy approvals, including highly sensitive detection of MTAP copy number loss. MTAP loss is present in approximately 15% of all cancer patients and is the target of several ongoing clinical trials, with the update addressing the significant technical challenge of detecting copy number losses in liquid biopsy.
Product Launch
Product Launch
BillionToOne has announced the launch of Northstar Origin, a tissue of origin add-on that uses QCT-based molecular counting of methylation to deliver 91% top 3 and 86% top 1 accuracy in identifying the tissue of origin. The product targets the approximately 3% of patients presenting with cancer of unknown primary, as well as the broader population of patients with uncertain diagnoses in community oncology settings, where uncertain diagnoses can affect up to 10% of patients.
Product Launch
Product Launch
BillionToOne has announced the launch of Unity Confirm, the first and only non-invasive confirmation assay for high-risk pregnancies, launched on May 28. Unity Confirm captures and sequences intact circulating fetal cells to provide 100% fetal fraction, offering patients who cannot or choose not to proceed to invasive diagnostic testing a non-invasive alternative as a specialized follow-on for high-risk pregnancies identified on the Unity Aneuploidy Screen.
Product Launch
Product Launch
Product Launch
BillionToOne News & Media
BillionToOne CTO sells 20,000 shares | BLLN Insider Trading - Stock Titan
CTO David Tsao exercised options for 20,000 shares at $2.80, then sold them up to $100.00 under a Rule 10b5-1 plan on Sep. 9, 2026.BillionToOne CTO converts, gifts 20K shares | BLLN Insider Trading - Stock Titan
CTO David Tsao converted 20,000 Class B into Class A shares, then made a bona fide gift of 20,000 Class A shares at $0.00, with 2.3M Class B still held.BillionToOne to Participate in the Wells Fargo 21st Annual Healthcare Conference
MENLO PARK, Calif., Sept. 2, 2026 /PRNewswire/ -- BillionToOne, Inc. (NASDAQ: BLLN), a next-generation molecular diagnostics company with a mission to create powerful and accurate tests that are accessible to all, today announced that Company management will participate in the Wells Fargo...Billiontoone (NASDAQ:BLLN) CTO David Tsao Sells 10,000 Shares - MarketBeat
Billiontoone, Inc. (NASDAQ:BLLN - Get Free Report) CTO David Tsao sold 10,000 shares of Billiontoone stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $100.00, for a total transaction of $1,000,000.00. Following the sale, the chief technology officer directly owned 1,000 shares in the company, valued at $100,000. This trade represents a 90.91% decrease in their ownership of the stock. The sale was disclosed in
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding BillionToOne
Sign Up For FreeTo access detailed company insights
BillionToOne, headquartered in Menlo Park, California, is a precision diagnostics company with a mission to make molecular diagnostics more accurate, efficient, and accessible for all. The company's patent-pending QCT molecular counter platform is the only technology platform that can accurately count DNA molecules to the single-count level. Billio... Read More
